In our report, the tumor cells of three patients were positive for MGMT, whose promoter methylation (Supplementary Figure S1) is considered a strong prognostic biomarker in pediatric and adult glioblastoma patients treated with TMZ [14, 15]. This evidence concerns the gene MGMT and neoplasm.